What does a CYP2C19 genotype mean for lifestyle?

The CYP2C19 genotype primarily affects the metabolism of certain medications, not lifestyle directly. This gene encodes a cytochrome P450 enzyme involved in breaking down drugs such as clopidogrel, proton pump inhibitors (e.g., omeprazole), and some antidepressants (e.g., escitalopram). Depending on the genotype (e.g., *1/*1 normal metabolizer, *2/*17 intermediate, or *17/*17 ultrarapid metabolizer), the efficacy or side-effect risk of these drugs can vary. For lifestyle aspects like diet, exercise, or sleep, there are no direct, clinically relevant effects. Some direct-to-consumer tests market CYP2C19 as a 'metabolism type,' but the evidence for that is weak and based on mechanistic reasoning, not robust lifestyle studies. The real relevance lies in pharmacogenetics: any drug dose adjustments should only be made by a physician. Without medication therapy, the genotype has no proven significance for everyday lifestyle decisions. The test results should be considered informative but not actionable for lifestyle changes.